Panobinostat Combination Delays Disease Progression in Myeloma
June 11th 2014Combining the pan-deacetylase inhibitor panobinostat with bortezomib and dexamethasone delayed disease progression by 3.9 months over bortezomib and dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma.
Read More
CD38-Specific Monoclonal Antibody Demonstrates Encouraging Efficacy in Myeloma
June 9th 2014SAR650984 demonstrated encouraging efficacy as a monotherapy and in combination with dexamethasone and lenalidomide without reaching a maximum tolerated dose in patients with heavily pretreated multiple myeloma.
Read More
Addition of ‘Smart’ Alkylator TH-302 to Dexamethasone Shows Benefit in Myeloma
June 6th 2014The addition of the investigational hypoxia-targeted drug TH-302 to dexamethasone has demonstrated beneficial activity and a manageable adverse event profile in the treatment of patients with relapsed/refractory multiple myeloma.
Read More
'Very, Very Impressive' Results Seen With Ipilimumab/Nivolumab Combination
June 4th 2014Phase I results presented in 2013 from a study combining ipilimumab with the anti-PD-1 antibody, nivolumab,1 showed a 40% objective response rate in 53 patients with advanced melanoma and a preliminary overall survival (OS) of 80%.
Read More
Pembrolizumab (MK-3475) Continues to Deliver Impressive Results in Melanoma
June 4th 2014Pembrolizumab continues to deliver impressive results in patients with advanced melanoma—producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.
Read More
Joint Analysis of Phase III Trials Will Change Practice in Premenopausal HR+ Breast Cancer
June 3rd 2014A joint analysis of two phase III trials involving a total of 4690 premenopausal women with HR+ breast cancer demonstrated that adjuvant use of exemestane reduced relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen.
Read More
14-Month Survival Benefit Demonstrated With Adding Chemo to ADT in Prostate Cancer
June 3rd 2014In what was described as “an almost unprecedented improvement in median survival,†the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.
Read More
Comparing Toxicities and Patient-Stated Preference in the SWOG S0307 Trial
June 3rd 2014Julie R. Gralow, MD, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.
Read More
Sirolimus and Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma
June 2nd 2014Filip Janku, MD, PhD, discusses a trial presented at the 2014 ASCO Annual Meeting looking at the activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated patients with refractory Hodgkin lymphoma.
Read More
Bevacizumab, Cetuximab Equally Effective in <em>KRAS</em> Wild-Type mCRC
June 2nd 2014Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with <em>KRAS</em> wild-type metastatic colorectal cancer (mCRC).
Read More
Dual HER2-Blockade Strategy With Lapatinib Fails in ALTTO Trial
June 2nd 2014A dual HER2-blockade strategy that added lapatinib to trastuzumab for the adjuvant treatment of women with early breast cancer failed to demonstrate a significant improvement in disease-free survival (DFS) over the standard therapy with trastuzumab alone.
Read More
Promise Seen With EGFR Inhibitor CO-1686 in Treatment-Resistant NSCLC
June 2nd 2014The third-generation EGFR inhibitor CO-1686 continues to demonstrate promising activity in patients with non–small cell lung cancer (NSCLC) who developed resistance after prior treatment with an EGFR tyrosine kinase inhibitor (TKI).
Read More
Effect of Ziv-Aflibercept in the Bevacizumab Pre-Treated Subgroup of Patients in VELOUR
June 1st 2014Paulo Marcelo Hoff, MD, PhD, FACP, discusses a trial that looked at the consistency of effect of ziv-aflibercept in the bevacizumab pre-treated subgroup of patients in the VELOUR trial stratified by first-line progression ≥ 9 months versus < 9 months.
Read More
Ibrutinib Dramatically Increases PFS, OS in Phase III CLL Study
June 1st 2014Treatment with single-agent ibrutinib (Imbruvica) dramatically increased progression-free survival (PFS) by nearly 80% and significantly extended overall survival (OS) by 57% compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Read More